IGF-1 LR3 1 mg

Compound profile

IGF-1 LR3: compound profile, literature landscape and handling notes

Where IGF-1 LR3 came from

Insulin-like growth factor 1 was characterized long before it was called that. It entered the literature as somatomedin C, one of the serum factors that appeared to mediate the growth-promoting activity of pituitary growth hormone rather than being that activity itself, and it was later recognized as a member of the insulin superfamily on structural grounds. Once the sequence was known and recombinant expression became routine, native-sequence human IGF-1 became available as a laboratory reagent and, separately, as a licensed protein under the name mecasermin.

The engineered variants came out of a specific and very practical problem in cell culture. In serum, and in any culture medium containing serum, the great majority of IGF-1 is not free. It is bound to a family of six high-affinity IGF binding proteins, IGFBP-1 through IGFBP-6, which sequester it, buffer its free concentration, and in some contexts present it to the receptor and in others withhold it. A researcher adding native IGF-1 to a serum-containing medium is therefore adding something whose free fraction is set by the binding-protein content of that particular batch of serum rather than by the amount weighed out. That is an unpleasant property in an experiment and an intolerable one in a manufacturing process.

The response was to engineer variants that the binding proteins recognize poorly. Two independent approaches emerged, both exploiting the same region of the molecule. One removed the first three N-terminal residues, giving the truncated form generally written as DES(1-3) IGF-1. The other, which is the material in this listing, combined a 13-residue N-terminal extension with a single substitution at position 3, giving Long R3 IGF-1. The extension also happens to make the construct convenient to express in a bacterial host, which is part of why this particular variant became the standard reagent for serum-free and low-serum media development rather than remaining a curiosity.

For a research buyer the useful piece of that history is that this molecule was designed as a process and cell-culture reagent first. Its literature reflects that, and it is a poor stand-in for native IGF-1 whenever binding-protein biology is part of what you are studying.

Reading the structure of IGF-1 LR3

The full sequence, formula and mass for this listing are printed in the specification table further down this page rather than restated here. What matters is reading the architecture behind those values, because it is genuinely different from every other entry in this catalog.

Start with the scaffold. Native human IGF-1 is a 70-residue single-chain protein with an insulin-like fold: A and B domains homologous to the insulin A and B chains, joined by a C domain that is retained rather than excised as insulin's C-peptide is, plus a short D extension. It is stabilized by three intramolecular disulfide bonds. That is a folded globular protein with a defined tertiary structure, not a flexible short chain that happens to adopt a helix at a receptor interface. Anything you know about how a 30-residue synthetic peptide behaves has to be re-derived here.

Onto that scaffold the LR3 construct adds two changes. The first is the 13-residue N-terminal extension that gives the molecule the Long in its name. The second is a single substitution at position 3 of the native numbering, where the glutamate of the native sequence is replaced by an arginine, which is the R3. Both modifications exist for the same reason, and this is the point most secondary descriptions get wrong by treating them as two unrelated features. The N-terminal region of IGF-1, and the glutamate at position 3 in particular, is a principal contact for the IGF binding proteins. Swapping an acidic residue for a basic one at that position disrupts the interaction. Hanging an unrelated 13-residue tail off the N-terminus disrupts it further, sterically as well as electrostatically. The net effect reported in the literature is a substantial reduction in affinity for the binding proteins while affinity for the receptor itself is much less affected.

The consequence that actually shows up on a bench is this: in a serum-containing medium, the free fraction of added IGF-1 LR3 is much higher than the free fraction of an equal mass of native IGF-1, and it is far less buffered, because the binding-protein reservoir that would normally absorb an excess and release it slowly is largely not engaging with this molecule. That is the whole reason the variant exists, and it is also the reason results obtained with it do not map cleanly onto native IGF-1 biology. The extension is not inert decoration and the substitution is not a stability tweak.

The target and the pathway in more detail

IGF-1 LR3 acts at the type 1 insulin-like growth factor receptor, IGF-1R, and that receptor belongs to a different structural and mechanistic class from the class B G-protein-coupled receptors that dominate the rest of this catalog. IGF-1R is a receptor tyrosine kinase. It is synthesized as a proreceptor that is cleaved into alpha and beta chains and assembled into a covalent heterotetramer, two alpha subunits and two beta subunits held together by disulfide bonds, which sits in the membrane as a preformed dimer even in the absence of ligand. There is no G protein, no cyclic AMP second messenger as the primary readout, and no ligand-induced dimerization step. Ligand binding to the extracellular alpha subunits instead drives a conformational rearrangement that brings the intracellular kinase domains into a productive geometry.

What follows is trans-autophosphorylation of tyrosines in the activation loop of the beta subunits, which raises kinase activity, followed by phosphorylation of additional tyrosines that create docking sites. Two principal branches propagate from there. Insulin receptor substrate proteins, chiefly IRS-1, are recruited and phosphorylated, providing binding sites for the regulatory subunit of phosphoinositide 3-kinase and leading through PIP3 and PDK1 to Akt, and onward to mTOR complex 1, GSK-3 and the FoxO transcription factors. The other branch runs through Shc and Grb2 to SOS, Ras, Raf, MEK and the ERK mitogen-activated protein kinases. In broad terms the published literature associates the first branch more with metabolic and survival readouts and the second more with proliferative ones, but the separation is a tendency rather than a rule and depends heavily on cell background.

The complication that matters most for interpreting any IGF-1R experiment is cross-reactivity. IGF-1R, the insulin receptor and the receptor for IGF-2 sit in an overlapping ligand space, and because both receptors are assembled from half-receptors in the same compartment, cells expressing both will also display IR/IGF-1R hybrid receptors composed of one alpha-beta half of each. Hybrids are not a laboratory artifact; they are present in tissue and their proportion tracks the relative expression of the two parent receptors. A readout obtained after adding an IGF-1 analog to a cell that expresses both receptors is therefore not automatically an IGF-1R readout. Establishing that it is requires a selective kinase inhibitor, a blocking antibody, a receptor-null or knockdown background, or at minimum a parallel insulin comparison, and a large amount of published and unpublished work on this compound does not include any of those.

What the published literature on IGF-1 LR3 actually measures

The published record that genuinely concerns IGF-1 LR3, as opposed to IGF-1 in general, falls into a few distinct bodies of work, and they are not equally useful.

The largest and most reliable body is cell culture and bioprocess literature. Long R3 IGF-1 has been studied and used for many years as a growth-supporting supplement in serum-free and reduced-serum media, including in industrial mammalian expression systems, where the practical questions are how much of it survives in medium over a culture cycle, whether it can substitute for insulin at far lower molar input, and how it interacts with the binding proteins that cells themselves secrete into conditioned medium. This is unglamorous work and it is where the compound's actual reported behavior is best documented.

The second body is receptor and signaling pharmacology, most of it done with native IGF-1 rather than with the LR3 variant. Autophosphorylation assays, IRS-1 phosphorylation, Akt and ERK phosphorylation time courses, and proliferation and survival assays in defined cell lines make up most of it. Where LR3 appears in this literature it is usually as a convenient binding-protein-resistant tool for showing that an effect attributed to IGF-1 is not simply an effect on binding-protein availability, which is a legitimate and rather elegant use of it.

The third body is in vivo rodent work, largely on muscle, bone, gut and neural tissue, some of it using the LR3 variant specifically because its altered clearance and reduced binding-protein capture change tissue exposure relative to native protein. This literature is real, but it is smaller than the volume of confident statements about this compound would lead you to expect, and its endpoints are tissue weights, histology and phosphorylation states rather than anything that transfers to another species.

A fourth category deserves naming precisely because it is so often mistaken for the third. A great deal of what circulates about this compound originates in bodybuilding forums, vendor copy and secondary articles that cite each other rather than any primary source. It is not peer-reviewed, it is not laboratory data, and it should not appear in a methods section or a literature review. When a claim about IGF-1 LR3 cannot be traced to a primary paper in two steps, the usual explanation is that there is no primary paper.

Where the IGF-1 LR3 literature is thin or frequently misread

The most common misreading of this compound is the simplest one: treating IGF-1 LR3 results as IGF-1 results. The variant was built specifically to escape the regulatory layer that governs native IGF-1 availability. Using it and then describing the outcome as what IGF-1 does inverts the logic of the experiment. If binding-protein biology is part of the system under study, LR3 is the wrong reagent; if it is a confound you are deliberately removing, LR3 is the right reagent and the paper needs to say so.

The second gap is the provenance problem described above. A large fraction of the circulated material on this compound is not from the peer-reviewed record at all, and quantitative claims in that material, particularly relative-potency claims against native IGF-1 or against insulin, tend to be repeated without a source. Where the genuine literature exists it is overwhelmingly cell culture and rodent, and the rodent work in particular is routinely over-extrapolated in secondary writing.

The third is receptor attribution, which is worth restating because it is specific to this receptor family. Without an insulin comparison, a selective inhibitor or a null background, an effect measured after adding this protein cannot be assigned cleanly to IGF-1R as opposed to the insulin receptor or to hybrid receptors. Reports that make the assignment without those controls are common.

The fourth is a handling point rather than a data point, and it belongs in the laboratory-practice column. IGF-1 signaling has a long and well-documented association with proliferation and with survival signaling in transformed cells, which is one of the more thoroughly established observations in the whole field. In a research setting that argues for an unusually clear containment, labeling and disposal record for this material: dedicated labware, decontamination of anything that contacted a working solution, and disposal through the same route as other biologically active protein reagents rather than down a sink. That is a statement about how a laboratory should manage a reagent, not health advice, and the relevant authority is your own institutional biosafety and waste procedure.

How IGF-1 LR3 behaves in solution

A recombinant protein is a considerably more fragile object in solution than a short synthetic peptide, and most of the handling problems reported with this material follow from that rather than from anything specific to the sequence.

Surface adsorption is the dominant loss mechanism, and it is worst under exactly the conditions typical of culture work: very dilute solutions, in the nanogram-per-milliliter range at the point of use, handled in tubes and plates with a large surface-to-volume ratio. A protein at that concentration can lose a large and unpredictable fraction of its content to a polypropylene wall or a pipette tip before it reaches the well. This is the main reason carrier protein, commonly bovine or human serum albumin at a low percentage, is added to working dilutions: it saturates the adsorptive sites so the analyte stays in solution. Carrier protein is a matrix change and has to be recorded, and it is incompatible with some downstream analytical work, so the decision belongs in the protocol rather than in a footnote.

Solubility is pH-dependent in the way any folded protein's is. IGF-1 and its variants are conventionally brought into solution in dilute acid, and acidic diluents are common for exactly that reason. Acid keeps the protein away from the pH at which its net charge is lowest and aggregation is most favorable, but it also means the concentrated stock is not at physiological pH and that transferring it into a buffered medium involves a pH transition where local precipitation can occur if it is done abruptly into a small volume.

Aggregation, once it starts, is not reversible in the way peptide association often is. A misfolded or partially unfolded protein exposes hydrophobic surface, and that surface nucleates further aggregation. Freeze-thaw cycling drives this hard, because the ice interface is where proteins unfold. Solutions that have gone this way may show visible haze or fine particulate, but they very often look perfectly clear while having lost most of their activity, which is why appearance is a poor release criterion here.

The 1 mg presentation is not an accident. Culture work consumes this material in extremely small amounts, protein solutions do not keep the way lyophilized material does, and a larger vial would mostly guarantee that most of it degraded before it was used.

Analytical notes specific to IGF-1 LR3

The analytical questions for a recombinant protein are not the same questions as for a synthetic peptide, and a certificate designed for the latter can look complete while leaving the ones that matter unanswered.

Begin with the impurity profile, which is set by the production route. Solid-phase synthesis produces deletion sequences, incomplete deprotection products and residual scavengers. Bacterial expression produces none of those and instead produces host-cell protein, host-cell DNA, endotoxin from the Gram- negative cell wall, species with incorrect or scrambled disulfide pairing, N-terminal heterogeneity from incomplete or over-enthusiastic processing of the initiator methionine and the leader region, methionine oxidation, deamidation, clipped forms generated by host proteases, and covalent or non-covalent aggregate. Endotoxin in particular has no analog in synthetic peptide work and matters for anything that will touch a cell, because it has its own potent biological activity and will generate signal that gets attributed to the protein.

The central point, and the one that most repays attention, concerns folding. This protein carries three intramolecular disulfide bonds. There are several ways those six cysteines can pair, only one of which is correct, and the incorrectly paired species have exactly the same molecular formula and exactly the same mass as the correct one. A mass-spectrometric identity result therefore cannot distinguish them. Neither, in general, can reversed-phase HPLC purity: disulfide isomers can co-elute, and even when they separate, an area-percent figure at a single wavelength tells you the peaks are different, not which peak is the folded protein. It is entirely possible to hold material that is mass-correct, chromatographically clean and biologically inert.

What answers the folding question is orthogonal. Non-reducing versus reducing SDS-PAGE run side by side is the classic and inexpensive approach: correctly folded, intramolecularly bonded protein is more compact and migrates differently under non-reducing conditions, disulfide-linked dimers and higher aggregates appear as bands that collapse to monomer on reduction, and comparing the two lanes tells you something no single-condition method does. Size-exclusion chromatography addresses aggregate state. Peptide mapping with and without reduction can assign the pairings directly. And a cell-based bioassay, receptor autophosphorylation or a proliferation readout in a responsive line, is the only method that answers the question you actually care about, which is whether the molecule works. For a recombinant protein, a functional assay is not an optional extra on top of the chemistry; it is the part of the package the chemistry cannot supply.

Compounds researchers confuse with IGF-1 LR3

Questions specific to IGF-1 LR3